3 Biotechs Making Waves: MRK, PFE, and GILD

Merck & Co., Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and Gilead Sciences, Inc. (NASDAQ:GILD) are making headlines today

Jul 28, 2015 at 11:54 AM
facebook twitter linkedin


Biotechs are in focus today, following earnings from a number of notable names -- as well as the latest round of news from headline-making Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). Drilling down, specific drugmakers grabbing the attention of Wall Street today include Merck & Co., Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and Gilead Sciences, Inc. (NASDAQ:GILD).

MRK reported better-than-expected second-quarter earnings and upped its full-year profit forecast amid growing demand for its diabetes and cancer treatments. Additionally, the company waxed optimistic over its $8.4 billion acquisition of Cubist Pharmaceuticals Inc, and said it bought cancer immunotherapy specialist cCAM Biotherapeutics. At last check, the security was up 0.6% at $57.35, after earlier bouncing from $56 -- an area that contained pullbacks in late October and mid-March.

Option traders, meanwhile, had been bracing for a post-earnings pullback. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Merck & Co., Inc.'s 10-day put/call volume ratio of 1.01 rests in the 81st annual percentile. Simply stated, puts have been bought to open over calls at a faster-than-usual clip in recent weeks.

Fellow Dow component PFE also unveiled its earnings report, with the firm's second-quarter results topping estimates. What's more, the company raised its full-year profit outlook, after global vaccine sales jumped 44%. The fundamental win has sent the shares 1.7% higher today to trade at $34.95. Longer term, PFE has tacked on 12.2% year-to-date, and is within striking distance of its April 13 10-year high of $35.53.

Similar to MRK, skepticism has been running high in PFE's options pits, per the stock's 10-day ISE/CBOE/PHLX put/call volume ratio of 1.23 -- in the 92nd percentile of its annual range. Plus, 63% of analysts still maintain a "hold" or "strong sell" rating on Pfizer Inc. Should the security continue its uptrend, a capitulation from option bears and/or a round of upgrades could help fuel its fire.

GILD -- which will step up to the earnings plate after tonight's close -- last night announced a pair of new additions to its senior leadership team. The stock initially swung 2.2% higher out of the gate, but was last seen up 0.7% at $111.28. Year-to-date, shares of GILD have added 18%, and after hitting an all-time high of $123.37 in late June, have pulled back to their rising 80-day moving average.

Call players have been flooding the equity's options pits in recent weeks. At the ISE, CBOE, and PHLX, Gilead Sciences, Inc.'s 10-day call/put volume ratio of 3.55 sits just 10 percentage points from a 52-week peak. Echoing this is the stock's gamma-weighted Schaeffer's put/call open interest ratio (SOIR) of 0.65, which indicates near-the-money call open interest outweighs put open interest among options expiring in three months or less.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners